Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II safety study of IFX-1 in moderate to severe hidradenitis suppurativa
2016-002988-33Phase 2Completed
- Sponsor
- InflaRx
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vilobelimab in hidradenitis suppurativa (HS), sponsored by InflaRx. Primary endpoint: Treatment emergent adverse events (Day 1–50 and Day 134). Started Oct 2016; status: completed.
02
Drugs
vilobelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2016-002988-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002988-33.